ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Overview of therapies for nonmetastatic castration-resistant prostate cancer (CRPC)

Overview of therapies for nonmetastatic castration-resistant prostate cancer (CRPC)
Approach Route,
schedule		 Contraindications HR for survival compared with placebo among men with advanced disease*
Enzalutamide Oral, daily Seizures

HR for MFS 0.29, 95% CI 0.24-0.35; median 36.6 versus 14.7 months[1]

HR for survival 0.73, 95% CI 0.61-0.89; median 67 versus 56 months[2]
Apalutamide Oral, daily –

HR for MFS 0.28, 95% CI 0.23-0.35; median 40.5 versus 16.2 months[3]

HR for 4-year overall survival 0.75, 95% CI 0.59-0.96; 72 versus 65%[4]
Darolutamide Oral, daily –

HR for MFS 0.41, 95% CI 0.34-0.50; median 40.4 versus 18.4 months[5]

HR for overall survival 0.69, 95% CI 0.53-0.88[6]
HR: hazard ratio; MFS: metastasis-free survival.
* The therapeutic approaches have not been compared with each other in large randomized trials. Only enzalutamide, apalutamide, and darolutamide have been evaluated in men whose only evidence of disseminated disease is an elevated or rising serum prostate-specific antigen (PSA).
References:
  1. Hussain M, Fizazi K, Saad F, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med 2018; 378:2465.
  2. Sternberg CN, Fizazi K, Saad F, et al. Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer. N Engl J Med 2020; 382:2197.
  3. Smith MR, Saad F, Chowdhury S, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med 2018; 378:1408.
  4. Small EJ, Saad F, Chowdhury S, et al. Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer. Ann Oncol 2019; 30:1813.
  5. Fizazi K, Shore N, Tammela TL, et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med 2019; 380:1235.
  6. Fizazi K, Shore ND, Tammela T, et al. Overall survival results of phase III ARAMIS study of darolutamide added to ADT for nonmetastatic castration-resistant prostate cancer (abstract). J Clin Oncol 2020; 38(suppl):abstr 5514.
Graphic 127196 Version 2.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟